OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals
Sarah E. Smith-Jeffcoat, Jessica E Biddle, H. Keipp Talbot, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 5, pp. 1175-1184
Open Access | Times Cited: 22
Sarah E. Smith-Jeffcoat, Jessica E Biddle, H. Keipp Talbot, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 5, pp. 1175-1184
Open Access | Times Cited: 22
Showing 22 citing articles:
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
Dallas J. Smith, Anastasia S. Lambrou, Pragna Patel
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1357-1364
Open Access | Times Cited: 21
Dallas J. Smith, Anastasia S. Lambrou, Pragna Patel
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1357-1364
Open Access | Times Cited: 21
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Emerging SARS-CoV-2 Resistance After Antiviral Treatment
Trevor J M Tamura, Manish C. Choudhary, Rinki Deo, et al.
JAMA Network Open (2024) Vol. 7, Iss. 9, pp. e2435431-e2435431
Open Access | Times Cited: 7
Trevor J M Tamura, Manish C. Choudhary, Rinki Deo, et al.
JAMA Network Open (2024) Vol. 7, Iss. 9, pp. e2435431-e2435431
Open Access | Times Cited: 7
COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment
Zhitao Yang, Yu Xu, Ruizhi Zheng, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241765-e241765
Open Access | Times Cited: 6
Zhitao Yang, Yu Xu, Ruizhi Zheng, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241765-e241765
Open Access | Times Cited: 6
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022
Patrick R. Harrington, Jie Cong, Stephanie B. Troy, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1365-1370
Open Access | Times Cited: 13
Patrick R. Harrington, Jie Cong, Stephanie B. Troy, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1365-1370
Open Access | Times Cited: 13
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19
Melisa M. Shah, Brendan Joyce, Ian D. Plumb, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 1, pp. 108-110
Open Access | Times Cited: 3
Melisa M. Shah, Brendan Joyce, Ian D. Plumb, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 1, pp. 108-110
Open Access | Times Cited: 3
Nirmatrelvir/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans
Liang En Wee, Jue Tao Lim, An Ting Tay, et al.
Clinical Microbiology and Infection (2024) Vol. 31, Iss. 1, pp. 93-100
Closed Access | Times Cited: 3
Liang En Wee, Jue Tao Lim, An Ting Tay, et al.
Clinical Microbiology and Infection (2024) Vol. 31, Iss. 1, pp. 93-100
Closed Access | Times Cited: 3
Analysis of Clinical Criteria for Discharge Among Patients Hospitalized for COVID-19: Development and Validation of a Risk Prediction Model
Jeffrey L. Schnipper, Sandra Oreper, Colin C. Hubbard, et al.
Journal of General Internal Medicine (2024) Vol. 39, Iss. 14, pp. 2649-2661
Open Access | Times Cited: 2
Jeffrey L. Schnipper, Sandra Oreper, Colin C. Hubbard, et al.
Journal of General Internal Medicine (2024) Vol. 39, Iss. 14, pp. 2649-2661
Open Access | Times Cited: 2
Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro
Manoj S. Nair, Maria I. Luck, Yaoxing Huang, et al.
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 2
Manoj S. Nair, Maria I. Luck, Yaoxing Huang, et al.
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 2
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Daniel M. Camp, Matthew Caputo, Fabiola Moreno Echevarria, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Daniel M. Camp, Matthew Caputo, Fabiola Moreno Echevarria, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Coronavirus Disease 2019 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: A Prospective Cohort Study
Jacqueline K. Kueper, Kalyani Kottilil, Giorgio Quer, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Jacqueline K. Kueper, Kalyani Kottilil, Giorgio Quer, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Repurposing Revisited: Exploring the Role of Metformin for Treatment of Coronavirus Disease 2019
Mark J. Siedner, Paul E. Sax
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 292-294
Closed Access
Mark J. Siedner, Paul E. Sax
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 292-294
Closed Access
Viral SARS-CoV-2 Rebound Rates in Linked Commercial Pharmacy-Based Testing and Health Care Claims
Scott P. Kelly, Lisa M. McEwen, Magnus Isaksson, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 6
Open Access
Scott P. Kelly, Lisa M. McEwen, Magnus Isaksson, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 6
Open Access
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
Ivan Gentile, G Agnese, Maria Michela Scirocco, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Ivan Gentile, G Agnese, Maria Michela Scirocco, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
COVID-19 clinical rebound after treatment with nirmatrelvir/ritonavir
Daniel M. Camp, Matthew Caputo, Fabiola Moreno Echevarria, et al.
Research Square (Research Square) (2024)
Open Access
Daniel M. Camp, Matthew Caputo, Fabiola Moreno Echevarria, et al.
Research Square (Research Square) (2024)
Open Access
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
Ivan Gentile, G Agnese, Maria Michela Scirocco, et al.
Research Square (Research Square) (2024)
Open Access
Ivan Gentile, G Agnese, Maria Michela Scirocco, et al.
Research Square (Research Square) (2024)
Open Access
Disparate SARS-CoV-2 infection outcomes abound, but what makes SARS-CoV-2 bound for rebound?
Timothy P. Sheahan
The Journal of Infectious Diseases (2024)
Open Access
Timothy P. Sheahan
The Journal of Infectious Diseases (2024)
Open Access
Discovery of a Nasal Spray Steroid, Tixocortol, as an Inhibitor of SARS-CoV-2 Main Protease and Viral Replication
David A. Davis, Ashwin Nair, Yana Astter, et al.
RSC Medicinal Chemistry (2024)
Closed Access
David A. Davis, Ashwin Nair, Yana Astter, et al.
RSC Medicinal Chemistry (2024)
Closed Access
Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial
Kara W. Chew, Brooke McGinley, Carlee Moser, et al.
The Journal of Infectious Diseases (2024)
Closed Access
Kara W. Chew, Brooke McGinley, Carlee Moser, et al.
The Journal of Infectious Diseases (2024)
Closed Access
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
Ivan Gentile, G Agnese, Maria Michela Scirocco, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Ivan Gentile, G Agnese, Maria Michela Scirocco, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
